TY - JOUR
T1 - Assessment 2 months after the administration of a 3rd dose mRNA
T2 - a new variant-adapted vaccine is expected
AU - Tré-Hardy, Marie
AU - Cupaiolo, Roberto
AU - Wilmet, Alain
AU - Antoine-Moussiaux, Thomas
AU - Coman-Vlagea, Nicoleta
AU - Della Vecchia, Andrea
AU - Horeanga, Alexandra
AU - Papleux, Emmanuelle
AU - Vekemans, Marc
AU - Beukinga, Ingrid
AU - Blairon, Laurent
N1 - Funding Information:
None declared. This study has been approved by the Ethical Committee of the HIS-IZZ (ethical agreement number: CEHIS/2021-007).
PY - 2022/4
Y1 - 2022/4
UR - http://www.scopus.com/inward/record.url?scp=85127756252&partnerID=8YFLogxK
U2 - 10.1016/j.jinf.2022.02.009
DO - 10.1016/j.jinf.2022.02.009
M3 - Letter
C2 - 35181372
AN - SCOPUS:85127756252
SN - 0163-4453
VL - 84
SP - e31-e33
JO - Journal of Infection
JF - Journal of Infection
IS - 4
ER -